Expression data comparing osimertinib-resistant H1975 and PC-9 cells, and cells that survive after treatment of those cells with a PAI-1 inhibitor

Even after osimertinib is administered to lung adenocarcinomas with EGFR mutations, there are a few cells which survive, and these tolerant cells are considered to be the source of later recurrence. We suspect that PAI-1 is involved in the regulation of these resistant cells and are currently investigating the role of PAI-1 in this process. We used microarray analysis to explore mechanisms involving PAI-1 behind the tolerance to osimertinib in lung adenocarcinoma cells with EGFR mutations. H1975 cells or PC-9 cells surviving 1 week after treatment with 0.5 µM osimertinib (OR) and those cells treated with 100 μM of SK-216, a PAI-1 inhibitor (OR+SK100) were collected and RNA was extracted and hybridized on Affymetrix microarrays.